A procedural framework for good imaging practice in pharmacological fMRI studies applied to drug development #2: protocol optimization and best practices.

Functional magnetic resonance imaging (fMRI) experiments are more complex compared with standard radiological imaging, involving additional data streams and hardware along with complex analysis methods. Here, we propose guidelines based around mitigating risks associated with the complexities of the technique at the level of the individual imaging protocol, including workable and effective quality assurance/quality control procedures and rigorous, predefined, analysis pipelines. Our aim is to provide a framework for 'good imaging practice' (GIP), enabling these requirements to be addressed at an appropriate level of detail. The development of a procedural framework for GIP in pharmaceutical fMRI studies could lead to greater acceptance of the method within industry and facilitate validation and, eventually, qualification of the technique as an imaging biomarker.

[1]  G. Iannetti,et al.  BOLD functional MRI in disease and pharmacological studies: room for improvement? , 2007, Magnetic resonance imaging.

[2]  Nick C Fox,et al.  The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods , 2008, Journal of magnetic resonance imaging : JMRI.

[3]  Janet Woodcock,et al.  The FDA critical path initiative and its influence on new drug development. , 2008, Annual review of medicine.

[4]  S C Williams,et al.  Quality control for functional magnetic resonance imaging using automated data analysis and Shewhart charting , 1999, Magnetic resonance in medicine.

[5]  Nick F. Ramsey,et al.  Within-subject variation in BOLD-fMRI signal changes across repeated measurements: Quantification and implications for sample size , 2008, NeuroImage.

[6]  Steven C. R. Williams,et al.  Measuring fMRI reliability with the intra-class correlation coefficient , 2009, NeuroImage.

[7]  Irene Tracey,et al.  Quantitative assessment of the reproducibility of functional activation measured with BOLD and MR perfusion imaging: Implications for clinical trial design , 2005, NeuroImage.

[8]  David B. Nash,et al.  Approaching the Evidence Basis for Aviation-Derived Teamwork Training in Medicine , 2010, American journal of medical quality : the official journal of the American College of Medical Quality.

[9]  David Borsook,et al.  Imaging in CNS Drug Discovery and Development , 2009 .

[10]  Ian Marshall,et al.  Functional Magnetic Resonance Imaging (fMRI) reproducibility and variance components across visits and scanning sites with a finger tapping task , 2010, NeuroImage.

[11]  Eric Achten,et al.  Incorporating Functional MRI into Clinical Pharmacology Trials , 2010 .

[12]  Karl Zilles,et al.  Automated quality assurance routines for fMRI data applied to a multicenter study , 2005, Human brain mapping.

[13]  Stephen M Smith,et al.  Variability in fMRI: A re‐examination of inter‐session differences , 2005, Human brain mapping.

[14]  S Strocchi,et al.  Multicenter trial for the set-up of a MRI quality assurance programme. , 2004, Magnetic resonance imaging.

[15]  Russell A. Poldrack,et al.  Guidelines for reporting an fMRI study , 2008, NeuroImage.

[16]  G H Glover,et al.  Image‐based method for retrospective correction of physiological motion effects in fMRI: RETROICOR , 2000, Magnetic resonance in medicine.

[17]  J. Ford,et al.  Widespread cortical dysfunction in schizophrenia: the FBIRN imaging consortium. , 2009, Schizophrenia bulletin.

[18]  J R Griffiths,et al.  Clinical studies. , 2005, Advances in pharmacology.

[19]  Anders Nilsson,et al.  A two-compartment gel phantom for optimization and quality assurance in clinical BOLD fMRI. , 2008, Magnetic resonance imaging.

[20]  D Gibon,et al.  Automatic quality assessment protocol for MRI equipment. , 1999, Medical physics.

[21]  Adrian Preda,et al.  Tuning in to the voices: a multisite FMRI study of auditory hallucinations. , 2009, Schizophrenia bulletin.

[22]  Sven Haller,et al.  Pitfalls in fMRI , 2009, European Radiology.

[23]  N. Logothetis.  What we can do and what we cannot do with fMRI , 2008, Nature.

[24]  Peter Steiger,et al.  Use of imaging biomarkers for regulatory studies. , 2009, The Journal of bone and joint surgery. American volume.

[25]  Jan D Schmitto,et al.  Scientific teamwork--a particular approach. , 2009, Kardiologia polska.

[26]  Owen Carmichael,et al.  Update on the Magnetic Resonance Imaging core of the Alzheimer's Disease Neuroimaging Initiative , 2010, Alzheimer's & Dementia.

[27]  J R Griffiths,et al.  Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials. , 2003, The British journal of radiology.

[28]  W. K. Simmons,et al.  Circular analysis in systems neuroscience: the dangers of double dipping , 2009, Nature Neuroscience.

[29]  David Borsook,et al.  A procedural framework for good imaging practice in pharmacological fMRI studies applied to drug development #1: processes and requirements. , 2011, Drug discovery today.

[30]  L. Lesko,et al.  Paving the Critical Path: How can Clinical Pharmacology Help Achieve the Vision? , 2007, Clinical pharmacology and therapeutics.

[31]  Peter A. Bandettini,et al.  Integration of motion correction and physiological noise regression in fMRI , 2008, NeuroImage.

[32]  C. Carter,et al.  Optimizing the Design and Analysis of Clinical Functional Magnetic Resonance Imaging Research Studies , 2008, Biological Psychiatry.

[33]  Daniel H. Mathalon,et al.  Using Brain Imaging Measures in Studies of Procognitive Pharmacologic Agents in Schizophrenia: Psychometric and Quality Assurance Considerations , 2011, Biological Psychiatry.

[34]  Gregory G. Brown,et al.  r Human Brain Mapping 29:958–972 (2008) r Test–Retest and Between-Site Reliability in a Multicenter fMRI Study , 2022 .

[35]  Massimo Filippi,et al.  Reproducibility of fMRI in the clinical setting: Implications for trial designs , 2008, NeuroImage.

[36]  David Borsook,et al.  Evaluation of novel drugs using fMRI in early-phase clinical trials: safety monitoring. , 2010, Drug discovery today.

[37]  John Suckling,et al.  Components of variance in a multicentre functional MRI study and implications for calculation of statistical power , 2008, Human brain mapping.

[38]  M. Brammer,et al.  Multisite fMRI reproducibility of a motor task using identical MR systems , 2007, Journal of magnetic resonance imaging : JMRI.

[39]  Lee Friedman,et al.  Report on a multicenter fMRI quality assurance protocol , 2006, Journal of magnetic resonance imaging : JMRI.

[40]  Gian Domenico Iannetti,et al.  Regions of interest analysis in pharmacological fMRI: How do the definition criteria influence the inferred result? , 2008, NeuroImage.

[41]  Bernhard Plattner,et al.  Decoding the Perioperative Process Breakdowns: a Theoretical Model and Implications for System Design , 2009 .

[42]  H. Pashler,et al.  Puzzlingly High Correlations in fMRI Studies of Emotion, Personality, and Social Cognition 1 , 2009, Perspectives on psychological science : a journal of the Association for Psychological Science.

[43]  I. Tracey,et al.  The role of fMRI in drug discovery , 2006, Journal of magnetic resonance imaging : JMRI.